Company Encyclopedia
View More
name
OMEGA THERAPEUTICS INC
OMGAQ.US
1.912 T
OMGAQ.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking351/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-166.90%E
    • Profit Margin-902.93%E
    • Gross Margin-256.32%E
  • Growth ScoreB
    • Revenue YoY185.04%A
    • Net Profit YoY32.35%B
    • Total Assets YoY-29.88%E
    • Net Assets YoY-84.82%E
  • Cash ScoreB
    • Cash Flow Margin-11.08%D
    • OCF YoY185.04%A
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreE
    • Gearing Ratio92.44%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets

    Feb 3 (Reuters) - Omega Therapeutics Inc:OMEGA THERAPEUTICS INC - ENTERS RESTRUCTURING SUPPORT AGREEMENTOMEGA THERAPEUTICS INC - POTENTIAL SALE OF ALL OR SUBSTANTIALLY ALL ASSETSOMEGA THERAPEUTICS INC: ENTRY INTO NEW FINANCING FACILITIES TO FUND SALE PROCESS AND WIND DOWN OF ANY REMAINING CO ASSETSOMEGA THERAPEUTICS INC: RESTRUCTURING COMMITTEE APPROVED A REDUCTION IN COMPANY’S CURRENT WORKFORCE BY UP TO 17 EMPLOYEES, EFFECTIVE IMMEDIATELY Source text: Further company coverage:

    Reuters·
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%
    Reuters·
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%

    Omega Therapeutics Announces Board Restructuring and Appointments

    Omega Therapeutics announced a board restructuring, with Ravi Mehrotra, Ph.D. and Robert L. Rosiello resigning from the Board of Directors on January 22, 2025. Jeffrey T. Varsalone was appointed as a Class I director on January 24, 2025, while Richard Kender was moved from Class III to Class II to rebalance the board. The company's current market cap is $28.18M, with a year-to-date price performance of -43.35%.

    Tip Ranks·
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%
    Tip Ranks·
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%

    Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California

    Omega Therapeutics :OMEGA THERAPEUTICS INC: ON JAN 13, RECEIVED NOTICE OF DEFAULT UNDER THE LOAN AND SECURITY AGREEMENT BETWEEN CO AND BANC OF CALIFORNIAOMEGA THERAPEUTICS INC - RESPONDS TO NOTICE OF DEFAULT, DENIES DEFAULT EVENTSOMEGA THERAPEUTICS INC: ATTEMPTED TO RESOLVE LOAN MATTER WITH BOC CONSENSUALLY, WHILE RESERVING RIGHTS TO LEGAL OR REGULATORY ACTION

    Reuters·
    US
    BANC
    -0.35%
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%
    Reuters·
    US
    BANC
    -0.35%
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%

    Omega Therapeutics Faces Leadership Change and Takeover Proposal

    Omega Therapeutics has announced the resignation of Michelle C. Werner from its Board of Directors. Additionally, the company received a non-binding takeover proposal from Mirai Bio, Inc., which includes assuming $8 million of Omega's debt. A special committee has been formed to evaluate this offer and explore strategic alternatives. Omega Therapeutics focuses on biotechnology, particularly in epigenetic and epigenomic controllers, and currently has a market cap of $44.48 million.

    Tip Ranks·
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%
    Tip Ranks·
    US
    OMGA
    0.00%
    US
    OMGAQ
    0.00%
    © 2025 Longbridge｜Disclaimer